Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05241262 · ClinicalTrials.gov registry record · Phase 1
Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels
A Phase 1 study of Mitochondrial Disease, sponsored by Michio Hirano, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT05241262 is a Phase 1 study of Mitochondrial Disease that is actively recruiting participants, run by Michio Hirano, MD. The registered enrollment target is 18 participants, below the 184-participant average among 5 other Mitochondrial Disease trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05241262, a Phase 1 study of Mitochondrial Disease, is actively recruiting participants, sponsored by Michio Hirano, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
N-Acetylcysteine (NAC), an anti-oxidant, will be studied to investigate the effects on brain glutathione levels, cognitive skills, motor skills, and quality of life. A group of 18 participants will take either 1800, 3600 or 5400 mg per day of N-acetylcysteine (NAC) for 3 months in this dose escalation study. The investigators want to determine first if the 3600 mg dose per day is safe and might provide some efficacy. If the 3600 mg dose is safe, then additional participants will be treated with 5400 mg per day of NAC, for up to a total of 18 participants. If the 3600 mg per day dose is unsafe, then participants will be treated with the 1800 mg per day dose. Data from this pilot study will be used to determine the most safe and effective dose of NAC for a future clinical trial.
Conditions Studied
Interventions
- DRUG N-Acetylcysteine
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2023-07-06 |
| Est. Completion | 2026-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05241262
The ClinicalTrials.gov registry entry for NCT05241262 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 184-participant average among 5 other Mitochondrial Disease trials with a reported enrollment target (90% lower). The listed sponsor is Michio Hirano, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Mitochondrial Disease appearing as the primary indexed condition, and to 1 intervention - of which N-Acetylcysteine is the first listed.
NCT05241262 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT05241262 about?
NCT05241262 is a clinical study titled "Study of N-acetylcysteine in the Treatment of Patients With the m.3243A>G Mutation and Low Brain Glutathione Levels". N-Acetylcysteine (NAC), an anti-oxidant, will be studied to investigate the effects on brain glutathione levels, cognitive skills, motor skills, and quality of life. A group of 18 participants will take either 1800, 3600 or 5400 mg per day of N-acetylcysteine (NAC) for 3 months in this dose escalat...
What is the current status of trial NCT05241262?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2023-07-06. Estimated completion is 2026-03.
What conditions does trial NCT05241262 study?
This clinical trial studies the following conditions: Mitochondrial Disease.
What interventions are being tested in trial NCT05241262?
The interventions under investigation include: N-Acetylcysteine (DRUG).
Who is sponsoring clinical trial NCT05241262?
This trial is sponsored by Michio Hirano, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05241262 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mitochondrial Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Validation of Nanosensor Oxygen Measurement
RECRUITING · Phase 1
-
Acute Infection in Mitochondrial Disease: Metabolism, Infection and Immunity
RECRUITING
-
Mitochondrial Dysfunction in Autism Spectrum Disorder
ACTIVE NOT RECRUITING
-
Assessment of Small Fiber Neuropathy in Rare Diseases Using Sudoscan
COMPLETED · NA
-
Mechanisms of Mitochondrial Defects in Gulf War Syndrome
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.